HighTower Advisors
PRME icon

HighTower Advisors’s Prime Medicine PRME Stock Holding History

HighTower Advisors’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.26M Buy
340,365
+110
+0% +$365 ﹤0.01% 2097
2026
Q1 		$1.18M Sell
340,255
-59,855
-15% -$228K ﹤0.01% 2072
2025
Q4 		$1.39M Buy
400,110
+66,355
+20% +$295K ﹤0.01% 1902
2025
Q3 		$1.85M Buy
333,755
+312,401
+1,463% +$1.27M ﹤0.01% 1678
2025
Q2 		$52.7K Sell
21,354
-292
-1% -$450 ﹤0.01% 3542
2025
Q1 		$43.1K Buy
21,646
+56
+0.3% +$143 ﹤0.01% 3465
2024
Q4 		$63K Sell
21,590
-85
-0.4% -$298 ﹤0.01% 3432
2024
Q3 		$83K Sell
21,675
-559
-3% -$2.59K ﹤0.01% 3344
2024
Q2 		$113K Sell
22,234
-52
-0.2% -$315 ﹤0.01% 3177
2024
Q1 		$153K Buy
22,286
+1,169
+6% +$8.87K ﹤0.01% 3058
2023
Q4 		$185K Sell
21,117
-182
-0.9% -$1.4K ﹤0.01% 3039
2023
Q3 		$201K Sell
21,299
-23
-0.1% -$299 ﹤0.01% 2911
2023
Q2 		$310K Buy
+21,322
New +$298K ﹤0.01% 2540

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

HighTower Advisors's PRME Position: Q2 2026 in Review

HighTower Advisors increased its Prime Medicine (PRME) stake by 0.03% in Q2 2026, buying an estimated $365 and bringing the position to 340,365 shares worth $1.26M. The position accounts for ﹤0.01% of the portfolio, ranked #2097.

HighTower Advisors first reported a position in PRME in Q2 2023 and has held it in 13 quarters since. The position peaked at $1.85M in Q3 2025. 187 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • HighTower Advisors held 340,365 shares of Prime Medicine worth $1.26M as of Q2 2026.
  • HighTower Advisors bought 110 Prime Medicine shares in Q2 2026, an estimated $365.
  • Prime Medicine made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #2097 holding.
  • HighTower Advisors first reported a position in Prime Medicine in Q2 2023 and has held it in 13 quarters since.
  • HighTower Advisors's Prime Medicine position peaked at $1.85M in Q3 2025.
  • 187 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.